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Objective: To demonstrate the safety and efﬁcacy of balloonmitral
valvuloplasty in patients of rheumatic mitral stenosis and situs
inversus with dextrocardia.
Background: Distorted cardiac anatomy and cardiac malpositions
increase the complications of interatrial septal puncture and left
ventricular entry during balloon mitral valvuloplasty.
Methods: Five patients with rheumatic mitral stenosis and situs
inversuswith dextrocardiawere included in this study. Mean trans-
mitral gradient before balloon mitral valvuloplasty (18  6 mmHg)
was signiﬁcantly higher, while mitral valve area (MVA) (0.68
 0.4 cm2) was signiﬁcantly lower. All the ﬁve patients were young
(mean age of 32 years) and symptomatic (mean pulmonary artery
pressure 60 10mmHg). Left femoral venous and arterial approach
was used. Fluoroscopic imaging was performed without inverting
the images although the software for the same was available. The
interatrial septum was approached using ﬂuoroscopy guide with
needle directed towards the spine and keeping the pointer of Brock-
enbrough needle at seven to eight O' clock position followed by
transatrial puncture in left lateral view. The transit across themitral
valve was done in left anterior oblique view without using pseudo
right anterior oblique imaging with just clockwise or counter clock-
wise guidewiremovement. Simultaneous transthoracic echocardio-
graphy guidance was used.
Results: Pre and post balloon mitral valvuloplasty hemodynamic
parameters were compared. Mean transmitral gradient before bal-
loon mitral valvuloplasty (18 6 mmHg) was signiﬁcantly higher,
while mitral valve area (MVA) (0.68 0.4 cm2) was signiﬁcantly
lower. All the ﬁve patients were young (mean age of 32 years) and
symptomatic (mean PA pressure 60 10 mmHg. After balloon
mitral valvuloplasty, mean PA pressure was signiﬁcantly reduced
– [33.5 12 mmHg], with a signiﬁcant reduction in transmitral gra-
dient (8.2  3.5 mmHg), with an increase in mitral valve area (2.1
 0.6 cm2).
Conclusion: This case series demonstrates the safety and efﬁcacy
of balloon mitral valvuloplasty without inverting the images on
ﬂuoroscopy.
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Introduction: MV repair remains standard of care in the world
today. It is different in India with RHD. MV repair summary data
by a single surgeon is presented here.
Methods: Prospective data on all MV repairs since 01/2004. Patients
were regularly followedupand thoseunable to comewere subject to
a telephonic interview alongwith review of their latest ECHO report.
Results: 163 patients underwentMV repair between 01/2004 and 06/
2015. The mean age of patients was 40 years (range 8–81). 58 (36%)
were female patients. 70 (43%) were RHD patients, 40 (25%) degen-
erativemitral valvedisease, 34 (21%) ischemicMR, 15(9%) congenital
MVdisease, 2(1%)withSBEand2(1%)withotheraetiologies.Majority
(144, 88%) patients had NYHA class III and above symptoms. The
mean EF was 53% (min 25% and max 79%). 10(6%) patients had
incidental mild to severe MS while the rest had Grade 3 and above
regurgitation.Meanpreopmitral annulus diameterwas 38 mm (Min
23, Max 50). More than moderate PA pressures were present in 69
(42%) patients. All procedures were performed via median sternot-
omy. The complexity of the repair was reﬂected on the number of
techniques needed to achieve competence. On an average, at least 2
techniqueswere necessary,while somepatients neededasmany as
6. Average follow up was 18 months in the cohort. The maximum
follow up time was 96 months. 44 patients were lost to follow up.
There were 2 deaths in the whole dataset, 1 was post operative
mortality and one at 12 months follow up. Three patients had
signiﬁcantmitral regurgitation on followup, one of whomhas been
reoperated. All of these patients were RHD.
Conclusion: Mitral valve repair, in expert hands provides good long
term outcome, free from reoperation. Moreovermorbidity andmor-
tality related to anticoagulant therapy was signiﬁcantly minimized
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Background: The predisposition to atrial ﬁbrillation (AF) in mitral
stenosis (MS) has been demonstrated with several electrocardio-
graphic (increased P-wave dispersion) and echocardiographic para-
meters (atrial electromechanical delay). The effect of percutaneous
balloon mitral valvuloplasty (PBMV) on these parameters and the
onset of AF later have not been studied in detail till now.
Aim of the study: Acute (within 48 h) and short term (at 6 months)
effect of PBMV on P-wave dispersion (PWD) and atrial Electro-
Mechanical Delay (EMD) in patients of Mitral Stenosis and sinus
rhythm.
Method: 34 patients of MS have been studied till date with follow
up of 8 patients (study is ongoing and full data will be presented in
conference). 12 lead ECG and detailed Echocardiographic evalua-
tion was done for each patient one day before, at 48 hours after
PBMV and at 6 months. The P-wave dispersion was calculated
from12-lead ECG. Interatrial and intra-atrial EMDs were measured
by tissue Doppler echocardiography. These ECG and echocardio-
graphic parameters after PMBV were compared with baseline
values. Additionally at 6 months 24 hour Holter monitoring has
be planned to rule out paroxysmal AF.
Result: 34 patients of critical MS who underwent successful BMV
have been studied till date (24 females and 10 males, aged mean
28.74  8.55 years, with a mean MVA of 0.75  0.15 cm2). After
PMBV, there was signiﬁcant improvement in the interatrial EMD
(46.03  18.36 ms vs. 62.00  28.11, p < 0.01) and left-sided intra-
atrial EMD (34.65  16.94 vs.49.32  30.14, p < 0.01) compared to
baseline with no signiﬁcant change in right sided intraatrial
EMD (16.41  17.86 vs 15.65  13.34, p = 0.854). There was also sig-
niﬁcant decrease in PWD following PBMV compared to baseline
(34.12  12.74 vs 41.88  15.82, p < 0.01). In 8 patients who have
completed 6 months follow up, there was tendency of further
decrease in left sided EMD with no patient developing AF.
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Background: Rheumatic mitral valve disease is a common disease
in India. Even in the presence of preserved global LV function as
measured by EF, in some RHD patients, impairment in long-axis
function can occur early. Recently Impaired LV long- axis move-
ment (by TDI) & myocardial strain is sensitive indicator of early
myocardial dysfunction.
Aims and objectives: (1) To study TDI and its application in patients
of Rheumatic MV disease. (2) To study the tissue Doppler velocities
at the MV annulus. (3) To evaluate LV function in patients of
rheumatic MV disease using strain& strain rate imaging.
Material and methods: This is single center prospective observa-
tional study conducted in 50 patients (pts) with rheumatic MSwith
orwithoutMRwith sinus rhythm in addition to 50 controls (cls). Pts
with predecided inclusion& exclusion criteria were enrolled in this
study & echo was done tomeasure MPI (tie) index, TD velocities (at
the lateral MV annulus), Peak systolic myocardial velocity (Sm),
Early diastolic velocity (Em) & strain imaging (SI) measured from
averaged value of 6 LV segments from apical 4-C view.
Results: In this study mean age was 29.94  8.02 in pts and 33.18
 9.0 in cls. Mean EF was 57.98  2.527 in pts & 58.74  2.783 in cls
(p-.15). MeanMPI by TDIwas 4560  .02740 in pts & 3934  .03543 in
cls ( p < .0001). Mean Sm was 7.98  1.152 in pts & 13.44  1.740 in
cls ( p < .0001). Mean Em was 8.70  1.689 in pts & 16.18  1.945 in
cls ( p < .0001). Mean averaged peak sys strainwas 17.7820  1.1182
in pts& 21.9384  1.431 in cls ( p < .0001). Mean averaged strain rate
was 0.893  0.855 in pts & 1.455  0.142 in cls ( p < .0001).
Conclusion: Using TDI, our study revealed that the MPI was sig-
niﬁcantly increased in pts compared to control group. Moreover
Sm, Em velocity and peak strain and strain rate was signiﬁcantly
lower in patients compared to control group. Thus MPI, Sm & Em
velocity and strain imaging can be useful in the detection of
subclinical LV dysfunction in patients of rheumatic MV disease.
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Introduction: Prosthetic valve thrombosis is deﬁned as any
obstruction of the prosthesis by non-infective thromboticmaterial.
The diagnosis of PVT is made by a combination of clinical data
(sudden worsening of heart failure, absence of prosthetic valve
sounds, pulmonary edema, cardiogenic hock) and echocardiogra-
phy. PVT is a life threatening emergency and requires treatment at
the earliest. Reported incidence of thrombosis of prosthetic mitral
valve is 0.03–4.3% per year. Thrombectomy or valve replacement is
the conventional treatment with an associated mortality rate of
4.7–20%.
Thrombolysis is emerging as a promising alternative to surgery
with a success rate ranging from 75% to 83%. In recent years,
thrombolytic therapy has evolved as a substitute to surgery. Var-
ious thrombolytic treatments have been reported with variable
success rates including streptokinase, urokinase and recombinant
tissue plasminogen activators. Most patients in published series
have been treated with infusions of streptokinase or urokinase for
12–24 hours. However, the data on the use of tenecteplase (a
synthetic tissue plasminogen activator) is limited.
It has been used extensively in acutemyocardial infarction (includ-
ing in our institute) but its use in PVT treatment has rarely been
reported.
Aims and objectives: To study the efﬁcacy and safety of
single intravenous bolus administration of tenecteplase in the
management of patients presenting with thrombosis of prosthetic
mitral valves in comparison to the use of streptokinase.
Materials and methods: All patients who presented with symp-
toms, clinical ﬁndings and radiological reports suggestive of
thrombosis of prosthetic mitral valves and who were not willing
to undergo emergency mitral valve replacement were included in
this study. Patients who had contraindications to thrombolysis
were excluded.
Patients were offered both streptokinase and tenecteplase, choices
differed as per ﬁnancial constraints.
All consecutive patients presenting with thrombosis of prosthetic
mitral valve, in NYHA Class III/IV were included in study if they
were not willing to undergo emergency mitral valve replacement.
The diagnosis of thrombosis of prosthetic mitral valves was estab-
lished mainly by trans-thoracic or trans-esophageal echocardio-
graphy and/or ﬂuoroscopy.
Patients with contraindication for thrombolytic therapy were
excluded from the study (i.e., previous haemorrhagic stroke or
other stroke within one year or known intracranial neoplasm or
Active internal bleeding -excluding menses or suspected aortic
dissection).
The ﬁbrinolytic agent used was tenecteplase given in weight
adjusted dose. Fibrinolytic regimens used were streptokinase
and tenecteplase, 0.5 mg/kg IV bolus administered over 5 s.
Heparin infusion was usually introduced after ﬁbrinolytic ther-
apy. Heparin infusion to obtain a partial thromboplastin time
between 70 and 90 s was continued for one week and then
replaced by warfarin treatment adjusted to obtain optimal pro-
thrombin time and international normalized ratio. The efﬁcacy of
ﬁbrinolytic therapywas assessed fromhemodynamic parameters
derived from echographic examinations as well as on clinical
grounds.
We deﬁned success as:
 Full: hemodynamic normalization conﬁrmed by cineﬂuoro-
scopy (normal mobility of tilting disks) or TTE/TEE data
(normalization of transprosthetic gradient and valve area,
normal mobility of leaﬂet, reappearance of click).
 Incomplete: signiﬁcant clinical improvement without com-
plete recovery of disc or leaﬂetmotion onﬂuoroscopy and/or
TTE.
 Failure: no clinical improvement, in many cases associated
with death or complications.
Results: Complete resolution of hemodynamic abnormalities was
seen in 13/13 patients who received tenecteplase while 16 out of
eighteen patients had complete resolutionwith streptokinase. One
patient had failure of therapy and succumbed to pulmonary edema
and another had partial resolution.
In patients who received tenecteplase, symptoms improvedmark-
edly, and prosthetic-valve clicks reappeared after a mean (SD)
period of 67.5  29 minutes (within 30 min in two patients).
No hemorrhagic complications were observed in any patients.
Two documented embolic event occurred during ﬁbrinolytic ther-
apy. (Brachial artery embolism, requiring embolectomy and stroke
due to embolism.)
None of the patients required subsequent surgery, and all were
alive and well after treatment and discharged in a stable condition
on warfarin in 7–10 days.
Treatment of patients with thrombosis of a prosthetic valve
remains controversial.
Our results in thirteen consecutive patients suggest that tenecte-
plase can be used safely in patients with prosthetic-valve throm-
bosis, resulting in rapid restoration of valve function as compared
the conventionally used streptokinase, beside ease of administra-
tion, i.e., bolus verses prolonged infusion.
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